Dr Adam Finn @ MRF's Meningitis & Septicaemia in children & Adults 2017

Meningitis Research Foundation
Meningitis Research FoundationMeningitis Research Foundation

Developments in the detection and understanding of meningococcal carriage, and implications for studies of the impact of MenB vaccines https://www.meningitis.org/mrf-conference-2017

15/11/2017
1
Developments in the detection and
understanding of meningococcal
carriage and implications for
studies of the impact of MenB
vaccines
@adamhfinn
MRF London 15th Nov 2017
tinyurl.com/adammrf2017
MenC changing
schedules
Birth 10  years 20  years
ACYW
tinyurl.com/adammrf2017
MenW cases in England,
2005/06-2014/15
tinyurl.com/adammrf2017
Cortesia de	
  S	
  Ladhani,	
  PHE,	
  RU Cortesia de	
  S	
  Ladhani,	
  PHE,	
  RU
2014/15
2015/16
2016/17
UK cumulative incidence of MenB
cases by age group 2011-2017
tinyurl.com/adammrf2017
Secondary endpoints
4CMenB vaccine
MenB Controls Efficacy
95%  CI
All  B 233/2489
9.4%
262/2576
10.2%
+15.6%
-­11.0  to  +35.9%
All  Nm 797/2489
32.0%
885/2576
34.4%
+18.2%
+3.4  to  +30.8%
B  C  W  Y 449/2489
18.0%
539/2576
20.9%
+26.6%
+10.5  to  +39.9%
Read  et  al.,  ESPID  2013,  Lancettinyurl.com/adammrf2017
Carriage studies
• Pfizer study – freezing and batching
• Portugal 1 – PCR and cx-amp PCR
• BrisMenNHC - longitudinal
– (MRF1) virology; GSK genogrouping
• Portugal 2 – saliva
• SPIT (MRF2&3) – lots more saliva
• Better understanding of biology
• Better sampling and lab methods
tinyurl.com/adammrf2017
15/11/2017
2
Throat Swabs / OPS
Direct  plating
Stored  STGG  broth
qPCR
tinyurl.com/adammrf2017
Meningococcal carriage
density in 87 young adults
0
5
10
15
20
25
30
35
40
45
50
0  to  <10 10  to  <100 100  to  <1000 1000  to  <10000
CFU/ml
Number  of  students
tinyurl.com/adammrf2017
Mening’ carriage density
Finn  et  al  PIDJ  2016
Culture  – left/hatched
qPCR  – right/solid
Upper  grey  sections  non-­concordant  results
tinyurl.com/adammrf2017
tinyurl.com/adammrf20
17
Oxford
Bristol V1 V2 V3 V4 V5 V6
Other  
centres
V
V
15-­19  year  olds
Into  1.5ml  STGG  
broth  on  site
Meningococci  
determined  by      
q-­PCR  for  sodC
Xfer  to  lab  within  
2-­6  hours  
frozen  -­80  °C  
Swab  and  questionnaire  at  each  time  point
£5  thank  you  for  their  time  for  V2-­6
BrisMenNHC
Density over time within
individuals appears highly
variable
tinyurl.com/adammrf20
17
0
1000
2000
3000
4000
5000
6000
Gene  copies/ml
Visit  date
Density over time within
individuals appears highly
variable
tinyurl.com/adammrf20
17
0
1000
2000
3000
4000
5000
Gene  copies/ml
Visit  date
15/11/2017
3
Density over time within
individuals appears highly
variable
tinyurl.com/adammrf20
17
0
200
400
600
800
1000
1200
Gene  copies/ml
Visit  date
Density over time within
individuals appears highly
variable
tinyurl.com/adammrf20
17
0
500
1000
1500
2000
2500
Gene  copies/ml
Visit  date
Density over time within
individuals appears highly
variable
tinyurl.com/adammrf20
17
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
Gene  copies/ml
Visit  date
tinyurl.com/adammrf20
17
Characteristic Group coeff 95%  CI p
Gender Female* 0  (reference) 0.020
Male 0.40 0.06 0.73
Age  group 15/16 0.15 -­0.24 0.54 0.218
17* 0  (reference)
18 -­0.38 -­0.80 0.03
19 0.38 -­1.12 1.88
School  year Year  12* 0  (reference) 0.006
Year  13 0.70 0.27 1.14
Other 0.18 -­1.77 2.14
Ethnicity White* 0  (reference) 0.033
Asian -­0.61 -­1.27 0.04
Black 0.50 -­0.31 1.32
Mixed/other -­0.76 -­1.53 0.01
Antibiotic  use None* 0  (reference) 0.073
Stopped  in  last  month0.67 -­0.04 1.39
Stopped  in  last  week 0.15 -­0.79 1.08
Currently  using -­0.68 -­1.41 0.05
Pub  days  in  week 0* 0  (reference) 0.068
1 0.10 -­0.19 0.38
2–7 0.54 0.08 0.99
Has  smoker  GF/BF No* 0  (reference) 0.076
Yes -­0.94 -­1.98 0.10
Month  of  year Jan* 0.00 0.00 0.00 0.193
Feb 0.02 -­0.37 0.40
Mar -­0.12 -­0.51 0.27
Apr 0.00 -­0.44 0.44
May -­0.37 -­0.88 0.14
Sep -­0.70 -­1.34 -­0.06
Oct -­0.16 -­0.64 0.32
Nov 0.15 -­0.27 0.58
Dec 0.17 -­0.34 0.68
Constant -­1.33 -­1.79 -­0.86 0.000
We found
• Gender
• School year
• Ethnicity
• Antibiotic use
• Pub visits
• Partner who
smokes
were associated
with Nm density
Density vs. month
tinyurl.com/adammrf2017
Associations between
Meningococcal Carriage &:
P=0.0564
P=0.0354
N.
meningitidis+
N.
meningitidis-
Total
Virus+ 14 105 119
Virus- 88 1173 1261
Total 102 1278 1380
RhV+ 12 81 93
RhV- 90 1197 1287
Total 102 1278 1380
Rhinovirus
Presence
Virus
Presence
N.B. Percentages as a proportion of total Viral/RhV +/-
12.9% 87.1% 100%
7.0% 93.0% 100%
11.8% 88.2% 100%
7.0% 93.0% 100%
tinyurl.com/adammrf2017
15/11/2017
4
Results-By Calendar Month
0
2
4
6
8
1 0
1 2
1 5
2 0
2 5
M o n th
Percentage(%)
F lu A
R S V
R h V
N . m e n in g it id is
S e p O ct N o v D e c J a n F e b M a r A p r
2 30 2 30 2 200 1 38 2 56 2 46 60n =
tinyurl.com/adammrf2017
See Liz
Oliver’s
poster here
Comparing methods
tinyurl.com/adammrf2017
1
45
87
2442
121
1493 46
66
1614
Culture
PCR
Culture  amplified
PCR
Cx 7.6%
PCR  8.8%
Cx+PCR 11.4%
CaPCR 15.9%
Cx+PCR+CaPCR 18.3%  
Multiple genogroups
Ø 5 of the 1,813 samples detect multiple genogroups in one sample run of qPCR
and the relevant Ct values
Ø Ct £ 36 – positive for Nm generic sodC and genogroups B, C, W, X and Y.
tinyurl.com/adammrf2017
See Kirsty
Nelson’s
poster here
Saliva
tinyurl.com/adammrf2017
Increasing sensitivity…
tinyurl.com/adammrf2017
N=1005  18-­25  year  old  medical/pharmacy  students
Coimbra,  Portugal
Increasing sensitivity…
tinyurl.com/adammrf2017
15/11/2017
5
All meningococci - PCR
tinyurl.com/adammrf2017
Throat  swabsSaliva
Direct
Culture-­amp’d
126
72
54
71
12.5%
19.6%
33.1%
136 34
33
5
20
23
11
52
14
5
36.1%
119
17
30
25
8
11
12
1419
6
GpB meningococci - PCR
tinyurl.com/adammrf2017
Throat  swabsSaliva
Direct
Culture-­amp’d
PCR  1.7%
+caPCR 3.1%
+Sal  3.3%
2
0
8
3
12
14
1+caPCR 3.6%
1
1
3
0
0
1
3
0
1
Gps BWXY meningococci - PCR
tinyurl.com/adammrf2017
Throat  swabsSaliva
Direct
Culture-­amp’d
PCR  2.2%
+caPCR 4.4%
+Sal  5.0%
4
0
10
3
19
14
1+caPCR 5.5%
4
2
5
0
1
1
3
0
2
SPIT
• 433 16-18 year olds – 419/397/296 V1-3
– Approx. 50% participation
• All offered 2 doses Bexsero
• OPS at vaccine visits & 3 months later
– 71% of V1s came for final swab
• Weekly salivas from pre-vaccine to end
• MRF have funded direct sodC PCR from
all OPS and salivas. Further funding needed
• Questionnaires on demographics and
motivation to take part…see Nicola Kelly’s
poster heretinyurl.com/adammrf2017
SPIT study
OPS/Saliva samples
tinyurl.com/adammrf2017
NanoString nCounter system
Gene detection &
counting nCounter
tinyurl.com/adammrf2017
15/11/2017
6
Conclusions
• Meningococcal carriage density is
dynamic – possibly driven by viral
infections
• Overall crude carriage rates in
vaccine recipients may be relatively
poor predictors of vaccine impact on
transmission
• Viable meningococci can be found in
saliva – implications for transmission
and precautions
tinyurl.com/adammrf2017
Conclusions
• Significant sampling and laboratory
methodological advances now available
to make carriage studies more sensitive
and informative.
• IMD not that rare – spend money on
vaccines not lottery tickets!
• Thanks to MRF for support
tinyurl.com/adammrf2017

Recommended

Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+ by
Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+
Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+Meningitis Research Foundation
6.6K views13 slides
Prof Rick Malley @ Meningitis & Septicaemia in Children & Adults 2017 by
Prof Rick Malley @ Meningitis & Septicaemia in Children & Adults 2017Prof Rick Malley @ Meningitis & Septicaemia in Children & Adults 2017
Prof Rick Malley @ Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
7.4K views40 slides
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017 by
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
7.2K views17 slides
Prof Adam Finn @ MRF's Meningitis and Septicaemia 2019 by
Prof Adam Finn @ MRF's Meningitis and Septicaemia 2019Prof Adam Finn @ MRF's Meningitis and Septicaemia 2019
Prof Adam Finn @ MRF's Meningitis and Septicaemia 2019Meningitis Research Foundation
4.8K views17 slides
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia by
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia Meningitis Research Foundation
8K views23 slides
Prof Kim Mulholland @ MRF's Meningitis & Septicaemia in Adults & Children by
Prof Kim Mulholland @ MRF's Meningitis & Septicaemia in Adults & ChildrenProf Kim Mulholland @ MRF's Meningitis & Septicaemia in Adults & Children
Prof Kim Mulholland @ MRF's Meningitis & Septicaemia in Adults & ChildrenMeningitis Research Foundation
7.5K views32 slides

More Related Content

What's hot

Confidence in numbers; the evidence base for assessing thepublic health impac... by
Confidence in numbers; the evidence base for assessing thepublic health impac...Confidence in numbers; the evidence base for assessing thepublic health impac...
Confidence in numbers; the evidence base for assessing thepublic health impac...Meningitis Research Foundation
2.2K views53 slides
Dr Matt Coldiron @ MRF's Meningitis and Septicaemia by
Dr Matt Coldiron @ MRF's Meningitis and SepticaemiaDr Matt Coldiron @ MRF's Meningitis and Septicaemia
Dr Matt Coldiron @ MRF's Meningitis and SepticaemiaMeningitis Research Foundation
6.6K views23 slides
GBSS' Jane Plumb @ MRF's Meningitis & Septicaemia in Children & Adults 2017 by
GBSS' Jane Plumb @ MRF's Meningitis & Septicaemia in Children & Adults 2017GBSS' Jane Plumb @ MRF's Meningitis & Septicaemia in Children & Adults 2017
GBSS' Jane Plumb @ MRF's Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
7.3K views10 slides
Dr Mark Alderson @ MRF's Meningitis and Septicaemia 2019 by
Dr Mark Alderson @ MRF's Meningitis and Septicaemia 2019Dr Mark Alderson @ MRF's Meningitis and Septicaemia 2019
Dr Mark Alderson @ MRF's Meningitis and Septicaemia 2019Meningitis Research Foundation
6.6K views25 slides
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017 by
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
6.8K views16 slides
Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017 by
Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017
Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017Meningitis Research Foundation
6.8K views10 slides

What's hot(20)

Similar to Dr Adam Finn @ MRF's Meningitis & Septicaemia in children & Adults 2017

beva in lung cancer.pptx by
beva in lung cancer.pptxbeva in lung cancer.pptx
beva in lung cancer.pptxDoQuyenPhan1
20 views51 slides
Advances in cholangiocarcinoma by
Advances in cholangiocarcinomaAdvances in cholangiocarcinoma
Advances in cholangiocarcinomaspa718
4K views51 slides
Localized Prostate Cancer in Puerto Rico by
Localized Prostate Cancer in Puerto RicoLocalized Prostate Cancer in Puerto Rico
Localized Prostate Cancer in Puerto Ricoflasco_org
75 views84 slides
Fall 2015 HIV Update by
Fall 2015 HIV UpdateFall 2015 HIV Update
Fall 2015 HIV Updatehivlifeinfo
979 views54 slides
Clinical Impact of New Data From AIDS 2018 by
Clinical Impact of New Data From AIDS 2018Clinical Impact of New Data From AIDS 2018
Clinical Impact of New Data From AIDS 2018hivlifeinfo
544 views55 slides
20171021 Personalized Prevention Strategy for Cervical Cancer by
20171021 Personalized Prevention Strategy for Cervical Cancer20171021 Personalized Prevention Strategy for Cervical Cancer
20171021 Personalized Prevention Strategy for Cervical CancerR.O.C.Ministry of Health and Welfare
694 views20 slides

Similar to Dr Adam Finn @ MRF's Meningitis & Septicaemia in children & Adults 2017(20)

beva in lung cancer.pptx by DoQuyenPhan1
beva in lung cancer.pptxbeva in lung cancer.pptx
beva in lung cancer.pptx
DoQuyenPhan120 views
Advances in cholangiocarcinoma by spa718
Advances in cholangiocarcinomaAdvances in cholangiocarcinoma
Advances in cholangiocarcinoma
spa7184K views
Localized Prostate Cancer in Puerto Rico by flasco_org
Localized Prostate Cancer in Puerto RicoLocalized Prostate Cancer in Puerto Rico
Localized Prostate Cancer in Puerto Rico
flasco_org75 views
Fall 2015 HIV Update by hivlifeinfo
Fall 2015 HIV UpdateFall 2015 HIV Update
Fall 2015 HIV Update
hivlifeinfo979 views
Clinical Impact of New Data From AIDS 2018 by hivlifeinfo
Clinical Impact of New Data From AIDS 2018Clinical Impact of New Data From AIDS 2018
Clinical Impact of New Data From AIDS 2018
hivlifeinfo544 views
Strategie di screening del cancro Colorettale - Gastrolearning® by Gastrolearning
Strategie di screening del cancro Colorettale - Gastrolearning®Strategie di screening del cancro Colorettale - Gastrolearning®
Strategie di screening del cancro Colorettale - Gastrolearning®
Gastrolearning719 views
Antiretroviral Therapy Update 2014 by hivlifeinfo
Antiretroviral Therapy Update 2014Antiretroviral Therapy Update 2014
Antiretroviral Therapy Update 2014
hivlifeinfo1.5K views
Antiretroviral Therapy Update 2014 by Hivlife Info
Antiretroviral Therapy Update 2014Antiretroviral Therapy Update 2014
Antiretroviral Therapy Update 2014
Hivlife Info9K views
Выбор начальной схемы АРТ у пациентов старшего возраста.Choosing and Using F... by hivlifeinfo
Выбор начальной схемы АРТ у  пациентов старшего возраста.Choosing and Using F...Выбор начальной схемы АРТ у  пациентов старшего возраста.Choosing and Using F...
Выбор начальной схемы АРТ у пациентов старшего возраста.Choosing and Using F...
hivlifeinfo1.3K views
Современное лечение ВИЧ: индивидуализация стартовой АРТ /Contemporary Manage... by hivlifeinfo
Современное лечение ВИЧ:  индивидуализация стартовой АРТ /Contemporary Manage...Современное лечение ВИЧ:  индивидуализация стартовой АРТ /Contemporary Manage...
Современное лечение ВИЧ: индивидуализация стартовой АРТ /Contemporary Manage...
hivlifeinfo471 views
Clinical Impact of New Data From AIDS 2020 by hivlifeinfo
Clinical Impact of New Data From AIDS 2020Clinical Impact of New Data From AIDS 2020
Clinical Impact of New Data From AIDS 2020
hivlifeinfo226 views
Incorporating New ART Options Into First-line and Switch Strategies for HIV C... by hivlifeinfo
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
hivlifeinfo696 views
ESMO Oesophageal cancer webinar.pdf by Farah Fara
ESMO Oesophageal cancer webinar.pdfESMO Oesophageal cancer webinar.pdf
ESMO Oesophageal cancer webinar.pdf
Farah Fara169 views
How I treat Relapsed Ca Ovary by Chandan K Das
How I treat Relapsed Ca OvaryHow I treat Relapsed Ca Ovary
How I treat Relapsed Ca Ovary
Chandan K Das312 views
Presentation 2.6 Research progress and biosecurity control strategies against... by ExternalEvents
Presentation 2.6 Research progress and biosecurity control strategies against...Presentation 2.6 Research progress and biosecurity control strategies against...
Presentation 2.6 Research progress and biosecurity control strategies against...
ExternalEvents1.2K views

More from Meningitis Research Foundation

Prof Rob Heyderman by
Prof Rob HeydermanProf Rob Heyderman
Prof Rob HeydermanMeningitis Research Foundation
2K views11 slides
Marco safadi by
Marco safadiMarco safadi
Marco safadiMeningitis Research Foundation
2K views16 slides
Brenda kwambana adams by
Brenda kwambana adamsBrenda kwambana adams
Brenda kwambana adamsMeningitis Research Foundation
2K views8 slides
Professor Muhamed-Kheir Taha by
Professor Muhamed-Kheir TahaProfessor Muhamed-Kheir Taha
Professor Muhamed-Kheir TahaMeningitis Research Foundation
2.2K views9 slides
Potential use of MenABCWY vaccines by
Potential use of MenABCWY vaccinesPotential use of MenABCWY vaccines
Potential use of MenABCWY vaccinesMeningitis Research Foundation
2.2K views13 slides
Dr william hanage by
Dr william hanageDr william hanage
Dr william hanageMeningitis Research Foundation
2.2K views25 slides

More from Meningitis Research Foundation(20)

Recently uploaded

VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective by
VarSeq 2.5.0: VSClinical AMP Workflow from the User PerspectiveVarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
VarSeq 2.5.0: VSClinical AMP Workflow from the User PerspectiveGolden Helix
72 views24 slides
T1DM case example.pptx by
T1DM case example.pptxT1DM case example.pptx
T1DM case example.pptxNguyễn đình Đức
25 views17 slides
Lifestyle Measures to Prevent Brain Diseases.pptx by
Lifestyle Measures to Prevent Brain Diseases.pptxLifestyle Measures to Prevent Brain Diseases.pptx
Lifestyle Measures to Prevent Brain Diseases.pptxSudhir Kumar
627 views23 slides
The Art of naming drugs.pptx by
The Art of naming drugs.pptxThe Art of naming drugs.pptx
The Art of naming drugs.pptxDanaKarem1
11 views48 slides
Mitochondria : Powerhouse of the Cell by
Mitochondria : Powerhouse of the CellMitochondria : Powerhouse of the Cell
Mitochondria : Powerhouse of the CellPrime Education Academy
8 views17 slides
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad by
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Swetha rani Savala
10 views16 slides

Recently uploaded(20)

VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective by Golden Helix
VarSeq 2.5.0: VSClinical AMP Workflow from the User PerspectiveVarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
Golden Helix72 views
Lifestyle Measures to Prevent Brain Diseases.pptx by Sudhir Kumar
Lifestyle Measures to Prevent Brain Diseases.pptxLifestyle Measures to Prevent Brain Diseases.pptx
Lifestyle Measures to Prevent Brain Diseases.pptx
Sudhir Kumar627 views
The Art of naming drugs.pptx by DanaKarem1
The Art of naming drugs.pptxThe Art of naming drugs.pptx
The Art of naming drugs.pptx
DanaKarem111 views
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad by Swetha rani Savala
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Pulmonary Embolism for Nurses.pptx by Asraf Hussain
Pulmonary Embolism for Nurses.pptxPulmonary Embolism for Nurses.pptx
Pulmonary Embolism for Nurses.pptx
Asraf Hussain27 views
STR-324.pdf by phbordeau
STR-324.pdfSTR-324.pdf
STR-324.pdf
phbordeau19 views
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx by JubinNath2
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptxCMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
JubinNath27 views
PATIENTCOUNSELLING in.pptx by skShashi1
PATIENTCOUNSELLING  in.pptxPATIENTCOUNSELLING  in.pptx
PATIENTCOUNSELLING in.pptx
skShashi119 views
Peptic ulcer.pdf by UVAS
Peptic ulcer.pdfPeptic ulcer.pdf
Peptic ulcer.pdf
UVAS8 views
AntiAnxiety Drugs .pptx by Dr Dhanik Mk
AntiAnxiety Drugs .pptxAntiAnxiety Drugs .pptx
AntiAnxiety Drugs .pptx
Dr Dhanik Mk20 views
Myocardial Infarction Nursing.pptx by Asraf Hussain
Myocardial Infarction Nursing.pptxMyocardial Infarction Nursing.pptx
Myocardial Infarction Nursing.pptx
Asraf Hussain13 views

Dr Adam Finn @ MRF's Meningitis & Septicaemia in children & Adults 2017

  • 1. 15/11/2017 1 Developments in the detection and understanding of meningococcal carriage and implications for studies of the impact of MenB vaccines @adamhfinn MRF London 15th Nov 2017 tinyurl.com/adammrf2017 MenC changing schedules Birth 10  years 20  years ACYW tinyurl.com/adammrf2017 MenW cases in England, 2005/06-2014/15 tinyurl.com/adammrf2017 Cortesia de  S  Ladhani,  PHE,  RU Cortesia de  S  Ladhani,  PHE,  RU 2014/15 2015/16 2016/17 UK cumulative incidence of MenB cases by age group 2011-2017 tinyurl.com/adammrf2017 Secondary endpoints 4CMenB vaccine MenB Controls Efficacy 95%  CI All  B 233/2489 9.4% 262/2576 10.2% +15.6% -­11.0  to  +35.9% All  Nm 797/2489 32.0% 885/2576 34.4% +18.2% +3.4  to  +30.8% B  C  W  Y 449/2489 18.0% 539/2576 20.9% +26.6% +10.5  to  +39.9% Read  et  al.,  ESPID  2013,  Lancettinyurl.com/adammrf2017 Carriage studies • Pfizer study – freezing and batching • Portugal 1 – PCR and cx-amp PCR • BrisMenNHC - longitudinal – (MRF1) virology; GSK genogrouping • Portugal 2 – saliva • SPIT (MRF2&3) – lots more saliva • Better understanding of biology • Better sampling and lab methods tinyurl.com/adammrf2017
  • 2. 15/11/2017 2 Throat Swabs / OPS Direct  plating Stored  STGG  broth qPCR tinyurl.com/adammrf2017 Meningococcal carriage density in 87 young adults 0 5 10 15 20 25 30 35 40 45 50 0  to  <10 10  to  <100 100  to  <1000 1000  to  <10000 CFU/ml Number  of  students tinyurl.com/adammrf2017 Mening’ carriage density Finn  et  al  PIDJ  2016 Culture  – left/hatched qPCR  – right/solid Upper  grey  sections  non-­concordant  results tinyurl.com/adammrf2017 tinyurl.com/adammrf20 17 Oxford Bristol V1 V2 V3 V4 V5 V6 Other   centres V V 15-­19  year  olds Into  1.5ml  STGG   broth  on  site Meningococci   determined  by       q-­PCR  for  sodC Xfer  to  lab  within   2-­6  hours   frozen  -­80  °C   Swab  and  questionnaire  at  each  time  point £5  thank  you  for  their  time  for  V2-­6 BrisMenNHC Density over time within individuals appears highly variable tinyurl.com/adammrf20 17 0 1000 2000 3000 4000 5000 6000 Gene  copies/ml Visit  date Density over time within individuals appears highly variable tinyurl.com/adammrf20 17 0 1000 2000 3000 4000 5000 Gene  copies/ml Visit  date
  • 3. 15/11/2017 3 Density over time within individuals appears highly variable tinyurl.com/adammrf20 17 0 200 400 600 800 1000 1200 Gene  copies/ml Visit  date Density over time within individuals appears highly variable tinyurl.com/adammrf20 17 0 500 1000 1500 2000 2500 Gene  copies/ml Visit  date Density over time within individuals appears highly variable tinyurl.com/adammrf20 17 0 2000 4000 6000 8000 10000 12000 14000 16000 18000 Gene  copies/ml Visit  date tinyurl.com/adammrf20 17 Characteristic Group coeff 95%  CI p Gender Female* 0  (reference) 0.020 Male 0.40 0.06 0.73 Age  group 15/16 0.15 -­0.24 0.54 0.218 17* 0  (reference) 18 -­0.38 -­0.80 0.03 19 0.38 -­1.12 1.88 School  year Year  12* 0  (reference) 0.006 Year  13 0.70 0.27 1.14 Other 0.18 -­1.77 2.14 Ethnicity White* 0  (reference) 0.033 Asian -­0.61 -­1.27 0.04 Black 0.50 -­0.31 1.32 Mixed/other -­0.76 -­1.53 0.01 Antibiotic  use None* 0  (reference) 0.073 Stopped  in  last  month0.67 -­0.04 1.39 Stopped  in  last  week 0.15 -­0.79 1.08 Currently  using -­0.68 -­1.41 0.05 Pub  days  in  week 0* 0  (reference) 0.068 1 0.10 -­0.19 0.38 2–7 0.54 0.08 0.99 Has  smoker  GF/BF No* 0  (reference) 0.076 Yes -­0.94 -­1.98 0.10 Month  of  year Jan* 0.00 0.00 0.00 0.193 Feb 0.02 -­0.37 0.40 Mar -­0.12 -­0.51 0.27 Apr 0.00 -­0.44 0.44 May -­0.37 -­0.88 0.14 Sep -­0.70 -­1.34 -­0.06 Oct -­0.16 -­0.64 0.32 Nov 0.15 -­0.27 0.58 Dec 0.17 -­0.34 0.68 Constant -­1.33 -­1.79 -­0.86 0.000 We found • Gender • School year • Ethnicity • Antibiotic use • Pub visits • Partner who smokes were associated with Nm density Density vs. month tinyurl.com/adammrf2017 Associations between Meningococcal Carriage &: P=0.0564 P=0.0354 N. meningitidis+ N. meningitidis- Total Virus+ 14 105 119 Virus- 88 1173 1261 Total 102 1278 1380 RhV+ 12 81 93 RhV- 90 1197 1287 Total 102 1278 1380 Rhinovirus Presence Virus Presence N.B. Percentages as a proportion of total Viral/RhV +/- 12.9% 87.1% 100% 7.0% 93.0% 100% 11.8% 88.2% 100% 7.0% 93.0% 100% tinyurl.com/adammrf2017
  • 4. 15/11/2017 4 Results-By Calendar Month 0 2 4 6 8 1 0 1 2 1 5 2 0 2 5 M o n th Percentage(%) F lu A R S V R h V N . m e n in g it id is S e p O ct N o v D e c J a n F e b M a r A p r 2 30 2 30 2 200 1 38 2 56 2 46 60n = tinyurl.com/adammrf2017 See Liz Oliver’s poster here Comparing methods tinyurl.com/adammrf2017 1 45 87 2442 121 1493 46 66 1614 Culture PCR Culture  amplified PCR Cx 7.6% PCR  8.8% Cx+PCR 11.4% CaPCR 15.9% Cx+PCR+CaPCR 18.3%   Multiple genogroups Ø 5 of the 1,813 samples detect multiple genogroups in one sample run of qPCR and the relevant Ct values Ø Ct £ 36 – positive for Nm generic sodC and genogroups B, C, W, X and Y. tinyurl.com/adammrf2017 See Kirsty Nelson’s poster here Saliva tinyurl.com/adammrf2017 Increasing sensitivity… tinyurl.com/adammrf2017 N=1005  18-­25  year  old  medical/pharmacy  students Coimbra,  Portugal Increasing sensitivity… tinyurl.com/adammrf2017
  • 5. 15/11/2017 5 All meningococci - PCR tinyurl.com/adammrf2017 Throat  swabsSaliva Direct Culture-­amp’d 126 72 54 71 12.5% 19.6% 33.1% 136 34 33 5 20 23 11 52 14 5 36.1% 119 17 30 25 8 11 12 1419 6 GpB meningococci - PCR tinyurl.com/adammrf2017 Throat  swabsSaliva Direct Culture-­amp’d PCR  1.7% +caPCR 3.1% +Sal  3.3% 2 0 8 3 12 14 1+caPCR 3.6% 1 1 3 0 0 1 3 0 1 Gps BWXY meningococci - PCR tinyurl.com/adammrf2017 Throat  swabsSaliva Direct Culture-­amp’d PCR  2.2% +caPCR 4.4% +Sal  5.0% 4 0 10 3 19 14 1+caPCR 5.5% 4 2 5 0 1 1 3 0 2 SPIT • 433 16-18 year olds – 419/397/296 V1-3 – Approx. 50% participation • All offered 2 doses Bexsero • OPS at vaccine visits & 3 months later – 71% of V1s came for final swab • Weekly salivas from pre-vaccine to end • MRF have funded direct sodC PCR from all OPS and salivas. Further funding needed • Questionnaires on demographics and motivation to take part…see Nicola Kelly’s poster heretinyurl.com/adammrf2017 SPIT study OPS/Saliva samples tinyurl.com/adammrf2017 NanoString nCounter system Gene detection & counting nCounter tinyurl.com/adammrf2017
  • 6. 15/11/2017 6 Conclusions • Meningococcal carriage density is dynamic – possibly driven by viral infections • Overall crude carriage rates in vaccine recipients may be relatively poor predictors of vaccine impact on transmission • Viable meningococci can be found in saliva – implications for transmission and precautions tinyurl.com/adammrf2017 Conclusions • Significant sampling and laboratory methodological advances now available to make carriage studies more sensitive and informative. • IMD not that rare – spend money on vaccines not lottery tickets! • Thanks to MRF for support tinyurl.com/adammrf2017